Overview

A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
0
Participant gender:
All
Summary
A study of Avastin (bevacizumab) in combination chemotherapy in patients with metastatic cancer of the colon or rectum. The anticipated time on study treatment is until disease progression.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Bevacizumab
Camptothecin
Capecitabine
Irinotecan
Criteria
Inclusion Criteria:

- adult patients >=18 years of age;

- colon or rectal cancer, with metastases;

- >=1 measurable lesion.

Exclusion Criteria:

- previous systemic treatment for advanced disease;

- radiotherapy to any site within 4 weeks before study;

- daily aspirin (>325 mg/day), anticoagulants, or other medications known to predispose
to gastrointestinal ulceration;

- co-existing malignancies or malignancies diagnosed within last 5 years (except basal
cell cancer or cervical cancer in situ).